NSE: ACUTAAS | BSE: 543349

Expensive Star

Download real time

3440.30 125.20 (3.78%)

164.23% Gain from 52W Low

551.4K NSE+BSE Volume

NSE 18 Sep, 2026 3:31 PM (IST)

28,166.1

Market Cap

High in industry

Beta 1Year

Low volatility

Acutaas Chemicals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ACUTAAS, BSE:543349 Acutaas Chemicals Ltd.

Search Inside the pdf :

Acutaas Chemicals Ltd.

29 Jul 2026

3440.30

3.78%

Acutaas Chemicals Ltd – Strong Results and Margin Improvement

Accumulate: Acutaas Chemicals Ltd.

Target

Deven Choksey

Management reiterated its FY27 guidance of 25% revenue growth, with EBITDA margins expected to remain in line with FY26 levels. The company also maintains its long-term target of achieving INR 1,000 crore in CDMO revenue by FY28.

Acutaas Chemicals Ltd. is trading above all available SMAs

Acutaas Chemicals Ltd.

27 Jul 2026

3440.30

3.78%

Acutaas Chemicals: Q1FY27 Result Review

Buy: Acutaas Chemicals Ltd.

Target

IDBI Capital

Acutaas Chemicals registered healthy growth in Q1FY27 with Revenue, EBITDA and PAT rising by 59%, 122% and 68% respectively. In terms of seasonality Q1 tends to be the softest quarter with a strong ramp up over the financial year. Revenue of Advanced...

Acutaas Chemicals has gained 52.37% in the last 6 Months

Acutaas Chemicals Ltd.

04 May 2026

3440.30

3.78%

Acutaas Chemicals: Q4FY26 Result Review

Buy: Acutaas Chemicals Ltd.

Target

IDBI Capital

Acutaas Chemicals registered a robust performance in Q4FY26. Revenue, EBITDA and PAT registered strong growth of 40%,116% and 111% respectively on YoY terms. We believe the company can clock in PAT CAGR of 28% from FY26-FY28E riding strongly on several growth levers led by the CDMO business. Robust growth in the Fermion contract coupled with steady growth in the NonCDMO Business augur strongly for profitability prospects. We believe that strong traction in key molecules will continue along with further scale up of CDMO business with the increasing ramp up of the Ankleshwar unit. We have revised estimates upwards to factor in stronger margin profile. We value...

Acutaas Chemicals has gained 52.37% in the last 6 Months

Acutaas Chemicals Ltd.

04 May 2026

3440.30

3.78%

Strong FY26, CDMO Driven Growth

Accumulate: Acutaas Chemicals Ltd.

Target

Deven Choksey

We expect the company to grow its Revenue/EBITDA/PAT at a CAGR of 26.6% / 23.1% / 21.2% for the period of FY26-FY28.

Acutaas Chemicals has gained 52.37% in the last 6 Months

Acutaas Chemicals Ltd.

29 Jan 2026

3440.30

3.78%

Acutaas Chemicals: Q3FY26 Result Review

Buy: Acutaas Chemicals Ltd.

Target

IDBI Capital

Acutaas Chemicals registered a superlative performance in Q3FY26. Revenue, EBITDA and PAT registered strong growth of 43%,119% and 140% respectively on YoY terms. We believe the company can clock in PAT CAGR of 54% from FY25-FY28E riding strongly on several growth levers led by the CDMO business. Robust growth in the Fermion contract coupled with healthy growth in the NonCDMO Business augur strongly for profitability prospects. We believe that strong traction in key molecules will continue along with further scale up of CDMO business with the increasing ramp up of the Ankleshwar unit. We have revised estimates upwards to factor in stronger margin profile. We roll forward...

Acutaas Chemicals Ltd. is trading above all available SMAs

Acutaas Chemicals Ltd.

29 Jan 2026

3440.30

3.78%

ACUTAAS CHEMICALS LIMITED

Buy: Acutaas Chemicals Ltd.

Geojit BNP Paribas

Acutaas Chemicals Ltd (formerly Ami Organics), incorporated in 2004, is a leading advanced pharmaceutical intermediates manufacturer (85% FY25 revenue) and specialty chemicals (15%) with a strong presence across CDMO, advanced intermediates and emerging specialty chemistry platforms such as battery chemicals and semiconductor chemicals. The company supports over...

Number of FII/FPI investors increased from 257 to 331 in Jun 2026 qtr.

Acutaas Chemicals Ltd.

14 Nov 2025

3440.30

3.78%

At the Apex of Chemistry

Buy: Acutaas Chemicals Ltd.

FundsIndia

Strategic Expansion: Battery & semiconductor chemical segments

Acutaas Chemicals has gained 133.87% in the last 1 Year

Acutaas Chemicals Ltd.

27 Oct 2025

3440.30

3.78%

Strong quarter with robust growth and margin expansion.

Accumulate: Acutaas Chemicals Ltd.

Recommendation Target

Deven Choksey

Acutas Chemicals delivered robust revenue and profit growth, driven by strong performance in API and specialty chemicals segment.

Acutaas Chemicals has gained 52.37% in the last 6 Months

Acutaas Chemicals Ltd.

23 Oct 2025

3440.30

3.78%

Acutaas Chemicals: Q2FY26 Result Review

Buy: Acutaas Chemicals Ltd.

Target

IDBI Capital

Acutaas Chemicals registered a superlative performance in Q2FY26. Revenue, EBITDA and PAT registered strong growth of 24%,95% and 94% respectively on YoY terms. We believe the company will can clock in revenue CAGR of 25-30% for the next 2 years with margins upwards of 29%. The growth will be propelled by strong growth in the advanced pharma intermediates business owing to strong traction in CDMO business and targeting of more molecules which will go off patent. We believe that strong traction in key molecules will continue along with further scale up of CDMO business with the increasing ramp up of the...

Acutaas Chemicals has gained 52.37% in the last 6 Months

VOTE: Is Ami Organics Ltd. worth buying?

121 Votes:

Buy 78.51%

Sell 11.57%

Hold 9.92%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf